Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.

Chen, Xinhui; Cui, Xiaoming; Pognan, Nathalie; Quinlan, Michelle; Kapoor, Shruti; Rahmanzadeh, Gholamreza; Giovannini, Monica; Marbury, Thomas C

Chen, Xinhui; Cui, Xiaoming; Pognan, Nathalie; Quinlan, Michelle; Kapoor, Shruti; Rahmanzadeh, Gholamreza; Giovannini, Monica; Marbury, Thomas C.

Afiliación

Chen X; Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA.
Cui X; Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA.
Pognan N; Novartis Pharma SAS, Rueil-Malmaison, France.
Quinlan M; Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Kapoor S; Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Rahmanzadeh G; Novartis Pharma AG, Basel, Switzerland.
Giovannini M; Global Drug Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Marbury TC; Orlando Clinical Research Center, Orlando, Florida, USA.

Br J Clin Pharmacol ; 88(1): 91-102, 2022 01.

Article en En | MEDLINE | ID: mdl-34046915

Asunto(s)

Benzamidas; Hepatopatías; Adulto; Área Bajo la Curva; Humanos; Imidazoles; Triazinas

Palabras clave

capmatinib; hepatic impairment; pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Benzamidas / Hepatopatías Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google